Alamar Biosciences, Inc.(ALMR)
$30.64+0.09 (+0.29%)
ALMR
Alamar Biosciences, Inc. financials statements
$30.64
At close:+0.09 (+0.29%)
Alamar Biosciences, Inc. (ALMR) Ratios
34 Followers
Alamar Biosciences, Inc. Ratios
ALMR's free cash flow for Q3 2026 was $-15.20M. For the 2026 fiscal year, ALMR's free cash flow was decreased by $-463.00K and operating cash flow was $-14.73M. See a summary of the company’s cash flow.
| Ratios | Dec 25 |
|---|---|
| Liquidity Ratios | |
| Current Ratio | 3.99 |
| Quick Ratio | 2.37 |
| Cash Ratio | 1.26 |
| Solvency Ratio | -0.09 |
| Operating Cash Flow Ratio | -2.26 |
| Short-Term Operating Cash Flow Coverage | 0.00 |
| Net Current Asset Value | $ -204.24M |
| Leverage Ratios | |
| Debt-to-Assets Ratio | 0.30 |
| Debt-to-Equity Ratio | -0.26 |
| Debt-to-Capital Ratio | -0.35 |
| Long-Term Debt-to-Capital Ratio | -0.07 |
| Financial Leverage Ratio | -0.88 |
| Debt Service Coverage Ratio | -63.73 |
| Interest Coverage Ratio | -78.14 |
| Debt to Market Cap | 0.01 |
| Interest Debt Per Share | 0.63 |
| Net Debt to EBITDA | -0.46 |
| Profitability Margins | |
| Gross Profit Margin | 56.20% |
| EBIT Margin | -38.74% |
| EBITDA Margin | -33.54% |
| Operating Profit Margin | -42.22% |
| Pretax Profit Margin | -39.29% |
| Net Profit Margin | -40.18% |
| Continuous Operations Profit Margin | -40.18% |
| Net Income Per EBT | 102.28% |
| EBT Per EBIT | 93.04% |
| Return on Assets (ROA) | -21.30% |
| Return on Equity (ROE) | 18.76% |
| Return on Capital Employed (ROCE) | -26.95% |
| Return on Invested Capital (ROIC) | -26.47% |
| Return on Tangible Assets | -21.61% |
| Earnings Yield | -2.04% |
| Efficiency Ratios | |
| Receivables Turnover | 5.82 |
| Payables Turnover | 5.54 |
| Inventory Turnover | 0.84 |
| Fixed Asset Turnover | 2.03 |
| Asset Turnover | 0.53 |
| Working Capital Turnover Ratio | 0.92 |
| Cash Conversion Cycle | 428.89 |
| Days of Sales Outstanding | 62.72 |
| Days of Inventory Outstanding | 432.10 |
| Days of Payables Outstanding | 65.93 |
| Operating Cycle | 494.83 |
| Cash Flow Ratios | |
| Operating Cash Flow Per Share | -0.81 |
| Free Cash Flow Per Share | -0.90 |
| Dividend Paid and CapEx Coverage Ratio | -8.40 |
| Capital Expenditure Coverage Ratio | -8.40 |
| Operating Cash Flow Coverage Ratio | -1.29 |
| Operating Cash Flow to Sales Ratio | -0.72 |
| Free Cash Flow Yield | -4.10% |
| Valuation Ratios | |
| Price-to-Earnings (P/E) Ratio | -48.89 |
| Price-to-Sales (P/S) Ratio | 19.72 |
| Price-to-Book (P/B) Ratio | -9.21 |
| Price-to-Free Cash Flow (P/FCF) Ratio | -24.39 |
| Price-to-Operating Cash Flow Ratio | -27.30 |
| Price-to-Earnings Growth (PEG) Ratio | 0.00 |
| Enterprise Value Multiple | -59.26 |
| Enterprise Value | 1.47B |
| EV to EBITDA | -59.26 |
| EV to Sales | 19.87 |
| EV to Free Cash Flow | -24.59 |
| EV to Operating Cash Flow | -27.51 |
| Tangible Book Value Per Share | -2.42 |
| Shareholders’ Equity Per Share | -2.39 |
| Tax and Other Ratios | |
| Effective Tax Rate | -0.02 |
| Revenue Per Share | 1.12 |
| Net Income Per Share | -0.45 |
| Tax Burden | 1.02 |
| Interest Burden | 1.01 |
| Research & Development to Revenue | 0.50 |
| SG&A to Revenue | 0.48 |
| Stock-Based Compensation to Revenue | 0.04 |
| Income Quality | 1.80 |
Currency in USD

